Brenda Gumz
Overview
Explore the profile of Brenda Gumz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pereira A, Fernandes G, Braga G, Marchetti K, Mascarenhas C, Gumz B, et al.
Clin Colorectal Cancer
. 2020 Aug;
19(4):e264-e271.
PMID: 32741580
Background: Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also...
2.
Costa F, Gumz B
Eur Endocrinol
. 2018 Jun;
10(1):70-74.
PMID: 29872467
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years. Octreotide is a somatostatin analogue used in the treatment of NETs, and its...
3.
Riechelmann R, Weschenfelder R, Costa F, Andrade A, Bersch Osvaldt A, Quidute A, et al.
Ecancermedicalscience
. 2017 Feb;
11:716.
PMID: 28194228
Neuroendocrine tumours are a heterogeneous group of diseases with a significant variety of diagnostic tests and treatment modalities. Guidelines were developed by North American and European groups to recommend their...
4.
Etchebehere E, Santos A, Gumz B, Vicente A, Hoff P, Corradi G, et al.
J Nucl Med
. 2014 Aug;
55(10):1598-604.
PMID: 25168627
Unlabelled: There are different metabolic imaging methods, various tracers, and emerging anatomic modalities to stage neuroendocrine tumor (NET). We aimed to compare NET lesion detectability among (99m)Tc-hydrazinonicotinamide (HYNIC)-octreotide (somatostatin receptor...
5.
Kamp K, Gumz B, Feelders R, Kwekkeboom D, Kaltsas G, Costa F, et al.
Endocr Relat Cancer
. 2013 Sep;
20(6):825-31.
PMID: 24036133
Although (177)Lu-octreotate is an effective treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), some patients will fail or develop disease progression necessitating further treatment. We examined whether the safety and...
6.
Cossetti R, Bezerra R, Gumz B, Telles A, Costa F
World J Surg Oncol
. 2012 May;
10:82.
PMID: 22591909
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like...